Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 102,063 | 153,513 | 108,159 | 117,437 | 184,266 |
| Marketable Securities | 427,669 | 405,313 | 412,513 | 460,641 | 446,000 |
| Receivables | 36,761 | 58,293 | 41,456 | 47,310 | 40,005 |
| Other current assets | 98,103 | 111,113 | 133,012 | 116,757 | 94,707 |
| TOTAL | $664,596 | $728,232 | $695,140 | $742,145 | $764,978 |
| Non-Current Assets | |||||
| PPE Net | 422,806 | 428,003 | 427,358 | 424,020 | 347,102 |
| Investments And Advances | 65,308 | 62,580 | 93,301 | 90,374 | 81,567 |
| Intangibles | 85,266 | 86,187 | 87,127 | 88,068 | 88,998 |
| Other Non-Current Assets | 69,136 | 51,948 | 53,066 | 57,454 | 61,563 |
| TOTAL | $642,516 | $628,718 | $660,852 | $659,916 | $579,230 |
| Total Assets | $1,307,112 | $1,356,950 | $1,355,992 | $1,402,061 | $1,344,208 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 39,551 | 50,781 | 53,117 | 50,074 | 56,611 |
| TOTAL | $47,294 | $64,307 | $68,804 | $67,023 | $75,396 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 7,743 | 13,526 | 15,687 | 16,949 | 18,785 |
| Other Non-Current Liabilities | 145,630 | 151,286 | 138,438 | 138,744 | 64,834 |
| TOTAL | $321,735 | $325,739 | $323,150 | $327,962 | $245,830 |
| Total Liabilities | $369,029 | $390,046 | $391,954 | $394,985 | $321,226 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 305,375 | 303,161 | 299,335 | 298,833 | 298,485 |
| Common Shares | 816,533 | 802,341 | 794,469 | 791,668 | 790,068 |
| Retained earnings | -72,647 | -29,482 | -20,537 | 36,582 | 71,309 |
| Other shareholders' equity | -2,419 | -4,234 | -2,698 | -2,657 | -6,998 |
| TOTAL | $938,083 | $966,904 | $964,038 | $1,007,076 | $1,022,982 |
| Total Liabilities And Equity | $1,307,112 | $1,356,950 | $1,355,992 | $1,402,061 | $1,344,208 |